View Financial HealthApimeds Pharmaceuticals US 배당 및 자사주 매입배당 기준 점검 0/6Apimeds Pharmaceuticals US 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.공시 • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).공시 • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.공시 • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.공시 • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.공시 • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.공시 • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 APUS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: APUS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Apimeds Pharmaceuticals US 배당 수익률 vs 시장APUS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (APUS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (APUS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 APUS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 APUS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 APUS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: APUS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 11:43종가2026/05/22 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Apimeds Pharmaceuticals US, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 16Apimeds Pharmaceuticals US, Inc. announced delayed 10-Q filingOn 05/15/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 23Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual ReportApimeds Pharmaceuticals US, Inc. (the "Company") announced that on April 17, 2026, it received a notice of non-compliance (the "Notice") with the continued listing standards set in Section 1007 of the Company Guide of NYSE American LLC ("NYSE American"). The Notice was issued in connection with the Company's failure to timely file its Form 10-K for the fiscal year ended December 31, 2025 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). As disclosed in a Form 12b-25 filed with the SEC on March 31, 2026, the Company was unable to file the Form 10-K within the prescribed time period without unreasonable effort or expense due to (i) the continued preparation and finalization of the Company's financial statements for the fourth quarter and fiscal year ended December 31, 2025, and (ii) the additional time required for the Company's independent registered public accounting firm to complete its audit procedures. The Company expects to file the Form 10-K by April 30, 2026. While the Company is making substantial progress toward completion, there can be no assurance that the Form 10-K will be filed by such date. The Company's common stock will continue to be listed on the NYSE American under the ticker symbol "APUS" while it attempts to regain compliance with the listing standard noted, but will have an added designation of ".LF" to signify the Company's late filing status, which will remain in place until the Company regains compliance with the applicable listing standard. The April 2, 2026, trading halt on the Company's common stock remains in effect and is not currently affected by the receipt of the Notice. NYSE Regulation, which monitors whether an issuer listed on the NYSE American has timely filed its annual and interim reports with the SEC, has informed the Company that during the period ending on October 15, 2026 (the "Initial Cure Period"), the NYSE American will monitor the Company and the status of the Form 10-K and any subsequent annual or quarterly report that the Company fails to file by the applicable due date ("Subsequent Reports") until the Form 10-K has been filed with the SEC. If the Company fails to file the Form 10-K and any Subsequent Reports within the Initial Cure Period, the NYSE American may, in the NYSE American's sole discretion, allow the Company's securities to be traded for up to an additional six-month period (the "Additional Cure Period") depending on the Company's specific circumstances. NYSE Regulation has informed the Company that if the NYSE American determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. The NYSE American may, in its sole discretion, decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE American believes, in the NYSE American's sole discretion, that continued listing and trading of the Company's securities on the NYSE American is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company is making this announcement in compliance with Section 1007 of the Company Guide, which requires prompt disclosure of receipt of the Notice. The Notice also requires the Company to speak to the NYSE American within five days of the receipt of the Notice, which the Company will do.
공시 • Apr 01Apimeds Pharmaceuticals US, Inc. announced delayed annual 10-K filingOn 03/31/2026, Apimeds Pharmaceuticals US, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Mar 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Minguk Ji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$0 This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (US$0 market cap).
공시 • Mar 25+ 2 more updatesApimeds Pharmaceuticals Us, Inc. Removes Erick Frim as Chief Financial OfficerApimeds Pharmaceuticals US, Inc. removed Erick Frim as chief financial officer of the Company.
공시 • Feb 12Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100 (Apitox)Apimeds Pharmaceuticals US, Inc. and Lokahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. LT-100 is pure honeybee venom, with a long history of clinical investigation. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration (KFDA; now the Ministry of Food and Drug Safety [MFDS). Apimeds and Lokahi Therapeutics are now advancing the program in the U. S. by integrating its historical data with rigorous development standards.
공시 • Jan 03Apimeds Pharmaceuticals Us, Inc. Announces Removal of Erik Emerson from Board of Directors, Effective December 30, 2025Apimeds Pharmaceuticals US, Inc. announced that on December 30, 2025, the stockholders, acting by written consent, removed Erik Emerson from the Company's board of directors, effective as of that date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of common stock of the Company's voting power entitled to vote generally in the election of directors, and was taken with or without cause, in accordance with the Company's organizational documents and applicable law. The following remain members of the Company's board of directors: Elona Kogan, Jakap Koo, Carol O'Donnell, Dr. Bennett Weintraub, PhD.
공시 • Dec 11Apimeds Pharmaceuticals Us, Inc. Announces Board ResignationsApimeds Pharmaceuticals US, Inc. announced that on December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc., and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company's Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
공시 • Dec 10Apimeds Pharmaceuticals US, Inc. announced that it has received $100 million in fundingOn December 10, 2025, Apimeds Pharmaceuticals US, Inc. closed the transaction. The company raised $100,000,000 in the transaction.